for people ages 18 years and up (full criteria)
at UC Davis
study started
estimated completion
Principal Investigator
by Karen P Kelly (ucdavis)



The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

Official Title

A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies


Advanced Cancer Triple Negative Breast Cancer Pancreatic Cancer Non-small Cell Lung Cancer Renal Cell Carcinoma, Clear Cell Cutaneous Melanoma Castrate Resistant Prostate Cancer Epithelial Ovarian Cancer Metastatic Cancer Neoplasms Pembrolizumab


You can join if…

Open to people ages 18 years and up

  • Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer
  • Participants must have stopped other forms of treatment for the cancer
  • In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study
  • Participants must not be pregnant, and must agree to use birth control
  • Participants must have progressed through or be intolerant to therapies with known clinical benefit

You CAN'T join if...

  • Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids
  • Participant must not have cancer that has spread to the brain
  • Participant must not have received a vaccine within the last 30 days
  • Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery
  • Participant must not have an infection that is currently being treated


  • University of California, Davis - Health Systems accepting new patients
    Sacramento California 95864 United States
  • Cedars Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States

Lead Scientist at UC Cancer

  • Karen P Kelly (ucdavis)
    Professor, Hematology and Oncology. Authored (or co-authored) 166 research publications.


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Phase 1
Study Type
Last Updated